Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum Malaria
Key facts
- Who runs it
- Assistance Publique Hopitaux De Marseille
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 56 people enrolled
- Started
- 17 Jun 2025
- Ended
- 13 Sept 2025
- Type of study
- Interventional
- Treatments tested
- Questionnaire
- Record updated
- 5 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Male or female over 18 years of age
- Have been diagnosed with severe malaria according to WHO criteria and have been treated between 1/1/2018 and 321/12/2024 at the AP-HM
- Have been treated with Artesunate IV (MALACEF®) (at least one dose)
- Patient who has received information about the study and has not expressed opposition
- Patient benefiting or entitled to benefit from a social security scheme
Who cannot take part
- Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code (minor patients, patients of legal age under guardianship, curatorship or safeguard of justice, patients deprived of their liberty, pregnant or breast-feeding women),
- Patients with advanced neurodegenerative pathology pre-existing the malaria attack
- Persons who do not understand French
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Malaria, endemic in 85 countries, remains a major concern. By 2022, there will be 249 million cases and 608,000 deaths, 94% of them in Africa. In France, 4995 cases of imported malaria were reported in 2021, with 15% of severe forms and a fatality rate of 2.5%. Long-term sequelae, such as kidney failure and neurological disorders, are well documented in children, but few studies have focused on adults.
Read full original descriptionShow less
the main objective is to describe and estimate the frequency of long-term sequelae of severe imported malaria treated at our centre.
the aim is to compare long-term neurological sequelae between neuromalaria and severe malaria without neurological disorders. In addition, the investigator aim to identify the clinical, radiological and biological factors associated with sequelae in order to improve post-hospitalisation follow-up. Finally, the investigator aim to describe acute complications arising at diagnosis and during hospitalisation.
The group in the trial
- malaria patientOther group
Treatment: Questionnaire
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 December 2025